<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04804137</url>
  </required_header>
  <id_info>
    <org_study_id>RIPH3-RNI20-RICEPS</org_study_id>
    <nct_id>NCT04804137</nct_id>
  </id_info>
  <brief_title>Immune Response Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples and Microbioata Study</brief_title>
  <acronym>RICEPS</acronym>
  <official_title>Immune Response Under Immunotherapy in Metastatic Non-Small Cell Lung Cancer: Sputum, Blood Samples and Microbiota Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective pathophysiological exploratory monocentric study, focusing on adult patients with&#xD;
      non-small cell lung cancer (NSCLC) : non-squamous type without oncogenic addiction,&#xD;
      metastatic, treated with immune checkpoint inhibitors alone or in combination with&#xD;
      chemotherapy in front line at the CHRU de Tours, France.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The percentage of patients benefiting from immunotherapy is quite low and their systemic side&#xD;
      effects can sometimes be severe. One of the main difficulties is to identify before treatment&#xD;
      patients who will respond to immune checkpoint inhibitors. Currently, the selection is done&#xD;
      in a very large majority of cases on the expression of PD-L1 by the tumor. But this biomarker&#xD;
      is not sufficient to identify patients responding or not to immune checkpoint inhibitors. In&#xD;
      addition, factors extrinsic to the tumor, to its microenvironment and patient immunity may be&#xD;
      involved in the response to immunotherapy such as the microbiota.&#xD;
&#xD;
      The investigators therefore assume that the immune response in place during immunotherapy&#xD;
      treatment differs according to the profile of patient response to immunotherapy.&#xD;
&#xD;
      The main objective of this project is to describe local and systemic anti-tumor immune system&#xD;
      of patients responders or not to immune checkpoint inhibitors, but also whether the&#xD;
      immunological characterization of sputum could be a reflection of the microenvironment tumor.&#xD;
      The secondary objective is to study the intestinal microbiota tract of patients receiving&#xD;
      immunotherapy, depending on their consumption of antibiotics, and compare it to the pulmonary&#xD;
      microbiota.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immune and inflammatory response in the blood</measure>
    <time_frame>30 months</time_frame>
    <description>T cell sub populations assessed by their relative abundance, and will be expressed as a percentage of total T cells&#xD;
B lymphocytes&#xD;
Cytokine inflammatory profile: the level of activation/regulation, production of cytokines and cytotoxicity markers will be analysed as a percentage of cells expressing the markers or producing the cytokines in relation to the total cell population (e.g. HLA-DR+, CD38+, Bcl-2lo phenotype of CD8 T lymphocytes)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune and inflammatory response in the airways</measure>
    <time_frame>30 months</time_frame>
    <description>T cell sub populations assessed by their relative abundance, and will be expressed as a percentage of total T cells&#xD;
B lymphocytes&#xD;
Cytokine inflammatory profile: the level of activation/regulation, production of cytokines and cytotoxicity markers will be analysed as a percentage of cells expressing the markers or producing the cytokines in relation to the total cell population (e.g. HLA-DR+, CD38+, Bcl-2lo phenotype of CD8 T lymphocytes)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of gut microbiota</measure>
    <time_frame>30 months</time_frame>
    <description>characterisation of gut microbiota (16S rRNA sequencing)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of lung microbiota</measure>
    <time_frame>30 months</time_frame>
    <description>characterisation of lung microbiota (16S rRNA sequencing)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Non-squamous Lung Cancer</condition>
  <condition>Metastatic Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Group</arm_group_label>
    <description>adult patients with adenocarcinoma type non-small cell lung cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood</intervention_name>
    <description>Blood samples are taken at each visit to the day hospital for a programmed injection of immunotherapy.</description>
    <arm_group_label>Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sputum</intervention_name>
    <description>induced by saline aerosol sputum during each visit to the day hospital for a programmed injection of immunotherapy.</description>
    <arm_group_label>Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saliva</intervention_name>
    <description>spontaneous saliva during each visit to the day hospital for a programmed injection of immunotherapy.</description>
    <arm_group_label>Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stool</intervention_name>
    <description>Stool analyses will be carried out on a sample taken by the patient at home and brought back at the time of a day hospital.</description>
    <arm_group_label>Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample, stool, saliva, sputum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        adult patients suffering from adenocarcinoma type non-small cell lung cancer (NSCLC)&#xD;
        without oncogenic addiction, metastatic, treated by ICI alone or in combination with 1st&#xD;
        line chemotherapy at the Tours CHRU.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of 18 years or over&#xD;
&#xD;
          -  Diagnosis of metastatic NSCLC (Stage IV) adenocarcinoma only&#xD;
&#xD;
          -  Absence of oncogenic addiction (EGFR, ALK, ROS1, RET, MET, BRAF)&#xD;
&#xD;
          -  Treatment with ICI anti-PD1 or anti-PDL1 (pembrolizumab or atezolizumab) as 1st line&#xD;
             treatment alone or in combination with chemotherapy and/or anti-angiogenic&#xD;
             (bevacizumab).&#xD;
&#xD;
          -  1st injection of ICI, whether or not combined with chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under judicial protection&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  NSCLC of the epidermal or undifferentiated type&#xD;
&#xD;
          -  Opposition to data processing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marion FERREIRA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion FERREIRA</last_name>
    <phone>02 47 36 62 42</phone>
    <phone_ext>+33</phone_ext>
    <email>marion-ferreira@hotmail.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion FERREIRA</last_name>
      <phone>02 47 36 62 42</phone>
      <phone_ext>+33</phone_ext>
      <email>marion-ferreira@hotmail.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood sample</keyword>
  <keyword>sputum</keyword>
  <keyword>microbiota</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>saliva</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

